Other manufacturing industries

Myoridge Co. Ltd.

Myoridge Co. Ltd.

In regenerative medicine and drug discovery research, cell quality, cell functionality, and cell properties such as proliferation and gene expression vary substantially depending on the composition and concentration of the culture medium. We offer culture media optimization based on our library of culture media components including solutions, proteins, lipids, and low-molecular-weight components, which is our core technology. So far, we have developed MSC media that enhance proliferation while inhibiting mesenchymal stem cell senescence, T cell culture media that control the ratio of killer T cells and helper T cells, and other culture media. We hope this technology will be used by overseas pharmaceutical companies and companies developing cell therapy products.
Area of Interest
  • North America
  • Europe
  • Southeast Asia
  • East Asia (excluding China)
  • Oceania

Site-visit

Allowed or subject to conditions


SDGs we are working on
3.Good health and well-being 9.Industry, innovation, infrastructure

Registered Keyword
We offer culture media optimization plans that utilize our unique library of culture media components to address cell culture issues including cell phenotype, culture reproducibility, safety, and cost.
Introducing our culture media under development (1) Ex-MSC XF Medium: A serum- and xeno-free medium with a stable proliferative capacity for human mesenchymal stem cells. This medium is capable of maintaining high proliferation, surface marker expression, and good cell morphology. (2) Ex-iPS Cell Medium: A serum- and xeno-free medium with a stable proliferative capacity. Some cell lines can be cultured without attachment factor coating. (3) T Cell Medium: The CD4/CD8 ratio and the percentage of undifferentiated cells can be controlled by different medium compositions.